# Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma

> **NCT01824615** · PHASE2 · COMPLETED · sponsor: **Cathay General Hospital** · enrollment: 30 (actual)

## Conditions studied

- Ovarian Cancer
- Adverse Effects

## Interventions

- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT01824615
- **Lead sponsor:** Cathay General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2018-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01824615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01824615, "Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01824615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*